X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/26/2870226/0/en/JERAYGO-aprocitentan-recommended-for-approval-in-Europe-for-the-treatment-of-resistant-hypertension.html
https://www.idorsia.com/media/news/news-archive/media-release-details?id=3195250
https://www.prnewswire.com/news-releases/us-fda-approves-idorsias-once-daily-tryvio-aprocitentan--the-first-and-only-endothelin-receptor-antagonist-for-the-treatment-of-high-blood-pressure-not-adequately-controlled-in-combination-with-other-antihypertensives-302094474.html
https://pharmaphorum.com/news/jj-pulls-out-idorsia-deal-hypertension-drug
https://www.globenewswire.com/news-release/2023/06/26/2694683/0/en/New-Phase-3-data-with-aprocitentan-for-patients-with-resistant-hypertension-has-been-presented-at-the-European-Society-of-Hypertension-Annual-Meeting-2023.html
https://www.globenewswire.com/news-release/2022/12/20/2576762/0/en/Idorsia-submits-a-New-Drug-Application-to-the-US-FDA-for-aprocitentan-for-the-treatment-of-patients-with-difficult-to-control-hypertension.html
https://www.reuters.com/business/healthcare-pharmaceuticals/idorsia-submits-new-drug-application-fda-2022-12-20/
https://www.globenewswire.com/news-release/2022/11/07/2550266/0/en/The-Lancet-and-AHA-late-breaking-science-session-reports-significant-and-sustained-effect-of-aprocitentan-on-lowering-blood-pressure-for-patients-with-resistant-hypertension.html
https://www.globenewswire.com/news-release/2022/11/03/2548099/0/de/Invitation-to-Idorsia-s-webcast-and-conference-call.html
https://endpts.com/idorsia-claims-phiii-win-for-hypertension-drug-at-center-of-230m-jj-deal/
https://www.globenewswire.com/news-release/2022/05/23/2448034/0/de/Positive-Phase-3-study-with-aprocitentan-demonstrates-significant-antihypertensive-efficacy-in-patients-with-resistant-hypertension.html
https://www.biospace.com/article/unique-little-idorsia-scores-230m-r-and-d-deal-with-johnson-and-johnson/
http://www.fiercebiotech.com/biotech/idorsia-spins-out-j-j-actelion-1b-and-multi-drug-pipeline-sees-shares-jump-30-first-day
Market Place
Share 
